Product review: avelumab, an anti-PD-L1 antibody
Although immunotherapies have been employed for many decades, immune checkpoint inhibitors have only recently entered the oncologic landscape. Avelumab is a fully human monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby inhibiting immunosuppress...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2019-04-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|